Age Related Macular Degeneration Clinical Trial
Official title:
Evaluation of Multiple Assessment Modalities for the Detection and Characterisation of the Preclinical, Pre-symptomatic Stage of Neovascular Age-related Macular Degeneration
Neovascular or wet age-related macular degeneration (ARMD) is a retinal disease and is the
leading cause of sight loss in the over 50s; it constitutes a major public health problem
which will have an increasingly large impact as the population ages, because sight loss has
been associated with loss of independence, depression, social isolation, and falls.
Recent advances in medicine, and in particular the approval on behalf of the National
Institute for Health and Clinical Excellence (NICE) for use of ranibizumab (Lucentis) in wet
ARMD, have allowed this condition to be treated; however success is more likely when
treatments occur at a very early stage.
Unfortunately the early stages of wet ARMD do not cause symptoms and most cases are diagnosed
when irreversible retinal damage has already occurred.
In all stages of ARMD, even when no symptoms are present and non-invasive techniques
currently used in routine clinical practice are not sufficiently sensitive to identify
abnormalities, retinal function and possibly anatomy are abnormal.
This study will evaluate techniques that may be useful in flagging subjects with the
"preclinical" stages of the disease. This may allow early preventative measures to be taken,
in order to stop altogether the onset of blindness.
The study will focus mainly on colour contrast sensitivity, a simple but highly sensitive
technique to assess retinal function, to establish if people with wet ARMD can be identified
before symptoms develop. Other assessment modalities, evaluating either structure or function
of the retina, will also be employed in selected individuals to establish if they may be used
in the routine clinic; however it is already known that these modalities are not suitable for
all individuals, as they are more demanding time-wise and concentration-wise, and therefore
not universally suitable.
Neovascular age‐related macular degeneration (nARMD), which by definition affects the over
50s, accounts for more than 50% of visual impairment certifications in the United Kingdom1
and a recent study2 estimates the prevalence in the UK at 1.2% in individuals aged 50 or
more, 2.5% in those over 65, and 6.3% in those aged 80 or more. Neovascular ARMD is therefore
likely to become a much more significant issue as the population ages, unless steps are taken
now to find ways of limiting loss of vision: the same study2 suggests there are currently
263,000 cases of nARMD in the UK, but the number is set to increase by almost a third by the
year 2020. Importantly, individuals with poor vision also have a higher frequency of falls
and of depression compared to aged‐matched people with normal vision, and are likely to live
alone and have additional health problems3, 4. Therefore nARMD significantly impacts on
quality of life, to a much greater extent than appreciated by many health professionals: a
key study5 reported that even mild sight impairment results in a 17% decrease in quality of
life, whereas moderate and severe sight impairment result in a 40% and 63% decrease in
quality of life respectively. It should be noted that a 63% decrease in quality of life is
comparable to that encountered with advanced prostatic cancer with uncontrollable pain or a
severe stroke that leaves a person bedridden, incontinent and requiring constant nursing
care5.
The advent of anti‐VEGF therapy in nARMD and the approval of ranibizumab (Lucentis) in the UK
by the National Institute for Clinical Excellence (NICE) has dramatically improved the
prognosis of patients with nARMD: vision can frequently be maintained or even improved,
particularly if early detection and treatment occur6‐9. However it is currently difficult to
detect and monitor nARMD in its early stages and most individuals typically present to the
ophthalmologist only once a certain degree of irreversible damage has occurred. The hallmark
of nARMD is a choroidal neovascular membrane (CNV) 1, 10, 11, although changes occur locally
before a CNV develops, as follows:
1. Inflammatory mediators are released in the affected area and changes in metabolism
develop12‐15.
2. The retina affected by the insult gradually loses its function10‐12, 14‐18. It has yet
to be established at which point of CNV development the surrounding retina has
detectable functional and structural abnormalities, however a wealth of literature10‐12,
14‐19 suggests it starts when the patient is still asymptomatic and before currently
available non‐invasive imaging techniques are able to detect any abnormality. Many
studies10, 12, 17, 18, 20 indicate that the above mentioned changes in metabolism
determine abnormal function in the overlying photoreceptors/inner retina very early in
the disease process, with some cone populations affected more than others18, 20, 21. The
same studies suggest it is possible to detect this localised abnormal retinal function
early with colour contrast sensitivity (CCS), especially in the blue‐yellow (tritan)
axis. The investigators therefore propose this technique can be utilised to identify
people at risk of developing nARMD and those with the early, presymptomatic stage of the
disease. The study will also evaluate other modalities which test either structure or
function of the retina, to establish if any can be used for the early detection of
nARMD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 | |
Completed |
NCT00358345 -
PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
|
Phase 4 |